Spots Global Cancer Trial Database for A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
Official Title: Phase I Study to Determine the Effect of a High Fat Meal on the Pharmacokinetics of BMS-540215, the Active Metabolite of Brivanib Alaninate in Subjects With Advanced or Metastatic Solid Tumors
Study ID: NCT00437437
Conditions
Interventions
Study Description
Brief Summary: The purpose of this trial is to determine the effect of food versus a fasted state on single-dose pharmacokinetics of BMS-540215, the active metabolite of Brivanib alaninate
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dana-Farber Harvard Cancer Care, Boston, Massachusetts, United States
Wayne State University, Detroit, Michigan, United States
Duke University Medical Center-Dept Of Medicine, Durham, North Carolina, United States
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
